# Selank

> Evidence tier A — Controlled human trials · Mind · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/selank/

Also known as: TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro

## Quick answers

**What is Selank?**

A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia for anxiolytic and nootropic applications.

**How strong is the evidence for Selank?**

Tier A (controlled human trials) on the peptidemeta evidence scale. One small randomized trial (62 patients with anxiety disorders, selank vs medazepam, 2008; indexed in PubMed as an RCT), otherwise small Russian clinical studies; registered in Russia but not FDA/EMA-approved.

**Is Selank FDA-approved?**

No. Selank is not approved by the FDA for any use. Outside the US: Russia — Selank nasal drops 0.15% (Peptogen), registration ЛСР-003338/09.

**Is Selank banned in sport?**

No. Selank is not on the World Anti-Doping Agency Prohibited List.

**How does Selank work?**

Selank is a synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension for stability. It has been reported to modulate GABAergic neurotransmission and serotonin metabolism and to affect enkephalin-degrading activity in blood; it also retains immunomodulatory activity related to tuftsin.

**What is known about the safety of Selank?**

Registered as an anxiolytic in Russia. Published studies, mostly small and from Russian groups, report no sedation or motor impairment.

## Key facts

- **Evidence tier:** A (Controlled human trials)
- **FDA:** not approved
- **Other approvals:** Russia — Selank nasal drops 0.15% (Peptogen), registration ЛСР-003338/09
- **WADA:** not on the Prohibited List
- **Peptide:** yes
- **Sequence:** TKPRPGP (7 residues)
- **Formula:** C33H57N11O9
- **Molecular weight:** 751.9 g/mol
- **Routes studied:** Intranasal, Subcutaneous

## Overview

A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia for anxiolytic and nootropic applications. It modulates GABA and serotonin systems without sedation.

## Mechanism

Selank is a synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension for stability. It has been reported to modulate GABAergic neurotransmission and serotonin metabolism and to affect enkephalin-degrading activity in blood; it also retains immunomodulatory activity related to tuftsin.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Reduced anxiety without sedation
- Enhanced cognitive function under stress
- Immune system modulation
- Stabilized mood and emotional balance

## Safety & unknowns

Registered as an anxiolytic in Russia. Published studies, mostly small and from Russian groups, report no sedation or motor impairment. Not FDA-approved in the US.

## Studies

- Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). *Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia*. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/18454096/
  In 62 patients with generalized anxiety disorder or neurasthenia, selank and medazepam had similar anxiolytic effects, with selank also showing antiasthenic and stimulant effects; serum enkephalin-related measures were also assessed.

## Status sources

- [PubChem CID 11765600 — Selank](https://pubchem.ncbi.nlm.nih.gov/compound/11765600)
- [RLS drug register (Russia) — Selank](https://www.rlsnet.ru/drugs/selank-36612)
- [Zozulia et al., Zh Nevrol Psikhiatr 2008 (GAD study)](https://pubmed.ncbi.nlm.nih.gov/18454096/)
- [WADA Prohibited List 2026](https://www.wada-ama.org/en/resources/world-anti-doping-code-and-international-standards/prohibited-list)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.